Delaby, Constance
Estellés, Teresa
Zhu, Nuole
Arranz, Javier
Barroeta, Isabel
Carmona-Iragui, María
Illán-Gala, Ignacio
Santos-Santos, Miguel Ángel
Altuna, Miren
Sala, Isabel
Sánchez-Saudinós, M. Belén
Videla, Laura
Valldeneu, Sílvia
Subirana, Andrea
Tondo, Mireia
Blanco-Vaca, Francisco
Lehmann, Sylvain
Belbin, Olivia
Blesa, Rafael
Fortea, Juan
Lleó, Alberto
Alcolea, Daniel http://orcid.org/0000-0002-3819-3245
Funding for this research was provided by:
Instituto de Salud Carlos III (PI14/01126, PI17/01019 and PI20/01473, PI13/01532 and PI16/01825, PI18/00335, PI18/00435 and INT19/00016, PI17/01896 and AC19/00103)
National Institute on Aging (1R01AG056850-01A1; R21AG056974; and R01AG061566)
Generalitat de Catalunya (SLT006/17/125, SLT006/17/119, SLT002/16/408, 2017-SGR-547)
Fundació la Marató de TV3 (20141210, 044412, 20142610)
Fundació Bancaria La Caixa (DABNI)
Fundació Catalana Síndrome de Down and Fundació Víctor Grífols i Lucas
Fondation Jérôme Lejeune
Article History
Received: 15 September 2021
Accepted: 20 January 2022
First Online: 1 February 2022
Declarations
:
: The ethics committee of Hospital Sant Pau approved all procedures included in this study following the standards for medical research in humans recommended by the Declaration of Helsinki. All participants or their legally authorized representatives gave written informed consent before enrolment in the study.
: All authors revised the manuscript for content and provided critical feedback.
: Daniel Alcolea is employed by Hospital de la Santa Creu i Sant Pau and received research grants from Pla Estratègic de Recerca i Innovació en Salut (PERIS SLT006/17/125) and from Instituto de Salud Carlos III (PI18/00435 and INT19/00016). He participated in the advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Zambon S.A.U., Esteve, and from Krka Farmacéutica S.L.Constance Delaby is employed by Université de Montpellier and CHU de Montpellier. Declarations of interest: noneTeresa Estellés is employed by Biomedical Research Institute Sant Pau. Declarations of interest: noneNuole Zhu is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: noneJavier Arranz is employed by Biomedical Research Institute Sant Pau. Declarations of interest: noneIsabel Barroeta is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: noneMaría Carmona-Iragui is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: noneIgnacio Illán-Gala is supported by the Global Brain Health Institute (Atlantic Fellow for Equity in Brain Health and pilot award for global brain health leaders GBHI ALZ UK-21-720973) and the “Juan Rodés” grant from the Institute of Health Carlos III (JR20/00018).Miguel Santos-Santos is employed by Hospital de la Santa Creu i Sant Pau. He is funded by a “Juan Rodés” research grant from the Institute of Health Carlos III.Miren Altuna is employed by Biomedical Research Institute Sant Pau. Dr. Altuna is funded by a “Río Hortega” research grant from the Institute of Health Carlos III.Isabel Sala is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: noneM. Belén Sánchez-Saudinós is employed by Biomedical Research Institute Sant Pau. Declarations of interest: noneLaura Videla is employed by Fundació Catalana Síndrome de Down. Declarations of interest: noneSílvia Valldeneu is employed by Biomedical Research Institute Sant Pau. Declarations of interest: noneAndrea Subirana is employed by Biomedical Research Institute Sant Pau. Declarations of interest: noneMireia Tondo is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: noneFrancisco Blanco-Vaca is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: none.Sylvain Lehmann is employed by the University and the Hospital of Montpellier. He participated in advisory boards from Fujirebio-Europe and Roche.Olivia Belbin is employed by Biomedical Research Institute Sant Pau. Dr. Belbin is funded by a “Miguel Servet” research grant from the Institute of Health Carlos III.Rafael Blesa is employed by Hospital de la Santa Creu i Sant Pau and received research grants from Institute of Health Carlos III, Fundació Bancària Obra Social La Caixa, and Fundació La Marató de TV3. He participated in the advisory boards from Lilly and Nutricia, and he received speaker honoraria and travel funding from Novartis and Nutricia.Juan Fortea is employed by Hospital de la Santa Creu i Sant Pau and received research grants from Institute of Health Carlos III, National Institutes of Health, Fundació La Marató de TV3, and Pla Estratègic de Recerca i Innovació en Salut (PERIS). Dr. Fortea has served as a consultant for Novartis and Lundbeck; has received honoraria for lectures from Roche, NovoNordisk, Esteve, and Biogen; and served at advisory boards for AC Immune, Zambon, and Lundbeck.Alberto Lleó is employed by Hospital de la Santa Creu i Sant Pau and received research grants from CIBERNED, Institute of Health Carlos III, Generalitat de Catalunya (PERIS and AGAUR), and Fundación BBVA. He participated in the advisory boards from Fujirebio-Europe, Novartis, Roche Diagnostics, Otsuka Pharmaceutical, Nutricia, Zambón S.A.U., and Biogen and received speaker honoraria from Lilly, Biogen, KRKA, and Zambon.